Viridian Therapeutics' experimental treatment for chronic thyroid eye disease (TED) significantly reduced symptoms such as double vision and eye bulging in a late-stage study, sending its shares ...

Shares of Viridian Therapeutics Inc. VRDN fell in the extended session Monday after the biotech drug maker said it was making changes to its study design for a chronic thyroid eye disease therapy ...

Viridian plans to initiate the THRIVE-2 Phase 3 trial to evaluate the safety and efficacy of VRDN-001 in patients with chronic TED in Q3 2023, with topline data expected by the end of 2024.

Viridian Therapeutics said on Tuesday its experimental treatment helped significantly reduce symptoms of thyroid eye disease (TED) in a late-stage study, setting the stage to become the first ...

WALTHAM, Mass., May 30, 2025--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for ...

Viridian Therapeutics’ phase 3 thyroid eye disease (TED) clinical trial has hit its primary and secondary endpoints. But with Amgen’s Tepezza already on the market, the data leave scope to ...

Viridian has released phase 1/2 data on a small group of patients that suggests its thyroid eye disease candidate could rival Amgen-acquired Horizon.

Viridian is also advancing VRDN-003 as a potential best-in-class subcutaneous therapy for the treatment of TED, including two ongoing global phase 3 pivotal clinical trials, REVEAL-1 and REVEAL-2 ...

Viridian's thyroid eye disease drug veligrotug clears its first phase 3 trial, with data suggesting it could be competitive with Amgen's Tepezza.

Summary. Viridian's veligrotug delivered positive data from two phase 3 trials in active and chronic TED patients. The results from the THRIVE-2 trial in chronic TED patients show hints of ...

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in ...